Drugs / HRS-1780
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07557407 | May → Jun 2026 overdue | chronic kidney disease | Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06495931 | Jul → Aug 2024 | type 2 diabetes mellitus | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06344936 | Apr → Jul 2024 | chronic kidney disease | Shandong Suncadia Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT06039254 | Sep → Nov 2023 | chronic kidney disease | Shandong Suncadia Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05638126 | Feb → Dec 2023 | chronic kidney disease | Shandong Suncadia Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07470983 | Apr → Nov 2026 expected | primary aldosteronism | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06221059 | Mar 2024 → Mar 2025 | chronic kidney disease | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07708441 | Sep 2026 → Apr 2029 expected | resistant hypertension | Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07419828 | Mar 2026 → Apr 2030 expected | chronic kidney disease | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-1780 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07557407 ↗ |
| Known as | [14C]HRS-1780 | “A Mass Balance Study of [14C]HRS-1780 in Healthy Adult Male Subjects” NCT07557407 ↗ |
| Action | Inhibit | “HRS-1780, a selective non-steroidal mineralocorticoid receptor antagonist” PMID 39155700 ↗ Aug 2024 |
| Modality | Small molecule | “an oral selective non-steroidal mineralocorticoid receptor antagonist” PMID 39155700 ↗ Aug 2024 |
| Route | Oral | “an oral selective non-steroidal mineralocorticoid receptor antagonist” PMID 39155700 ↗ Aug 2024 |